Moderna vaccine reduced viral load and protected against SARS-CoV-2 variants in new phase 3 trial

Coronavirus research has shown that higher viral loads are associated with severe COVID-19 infection. But new results from the phase III Coronavirus Efficacy (COVE) clinical trial find the Moderna vaccine reduces severe acute respiratory coronavirus 2 (SARS-CoV-2) viral load and viral shedding.

Related Keywords

California ,United States ,Jocelyn Solis Moreirasep ,Jocelyn Solis Moreira ,Viral Dynamics ,Circulating Viral Variants During ,Initial Analysis ,Image Credit ,Coronavirus Disease Covid 19 ,Cars ,Ars Cov 2 ,Vaccine ,Ntibody ,Clinical Trial ,Coronavirus ,Efficacy ,Placebo ,Research ,Espiratory ,Evere Acute Respiratory ,